Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period-Reference-Cited by-同舟云学术

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Published:2019-06-04 Issue:3 Volume:105 Page:271-284
ISSN:0171-967X
Container-title:Calcified Tissue International
language:en
Short-container-title:Calcif Tissue Int

Author:

Portale Anthony A.,Carpenter Thomas O.,Brandi Maria Luisa,Briot Karine,Cheong Hae II,Cohen-Solal Martine,Crowley Rachel,Jan De Beur Suzanne,Eastell Richard,Imanishi Yasuo,Imel Erik A.,Ing Steven,Ito Nobuaki,Javaid Muhammad,Kamenicky Peter,Keen Richard,Kubota Takuo,Lachmann Robin,Perwad Farzana,Pitukcheewanont Pisit,Ralston Stuart H.,Takeuchi Yasuhiro,Tanaka Hiroyuki,Weber Thomas J.,Yoo Han-Wook,Zhang Lin,Theodore-Oklota Christina,Mealiffe Matt,San Martin Javier,Insogna Karl

Funder

Ultragenyx Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00223-019-00568-3.pdf

Reference21 articles.

1. The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136. https://doi.org/10.1038/ng1095-130

2. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663. https://doi.org/10.1056/nejmoa020881

3. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435. https://doi.org/10.1359/jbmr.0301264